{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:17:06Z","timestamp":1791821826137,"version":"4.3.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the pharmacology, efficacy, safety, and clinical use of datopotamab deruxtecan (Dato-DXd), a recently approved trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), in the treatment of advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>\n                      A comprehensive English-language literature search was conducted on PubMed and ClinicalTrials.gov from January 2010 through September 2025 using the search terms\n                      <jats:italic toggle=\"yes\">datopotamab, datroway, breast cancer<\/jats:italic>\n                      , or\n                      <jats:italic toggle=\"yes\">nonsmall cell lung cancer<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Evidence was gathered from clinical trials, relevant articles, guidelines, abstracts, and package inserts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Dato-DXd received accelerated approval by the Food and Drug Administration (FDA) in 2025 for hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer, and epidermal growth factor receptor (EGFR)-mutant nonsmall cell lung cancer (NSCLC). In the TROPION-Breast01 trial, Dato-DXd demonstrated superior efficacy with a response rate of 36.4% versus 22.9% for chemotherapy and median progression-free survival of 6.9 versus 4.9 months. In NSCLC, TROPION-Lung01 showed a response rate of 26.4% with Dato-DXd compared with 12.8% with docetaxel. For the approved EGFR-mutant NSCLC indication, the TROPION-Lung05 trial demonstrated a response rate of 35.8% with Dato-DXd. Treatment-related adverse events included stomatitis, nausea, alopecia, and ocular events, with interstitial lung disease\/pneumonitis representing the most clinically significant safety concern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice:<\/jats:title>\n                    <jats:p>The TROP2-directed ADC appears to be a viable therapeutic alternative for select patients with previously treated HR+\/HER2\u2013 breast cancer or EGFR-mutant NSCLC after progression on targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dato-DXd offers a promising treatment option for heavily pretreated patients with HR+\/HER2\u2013 breast cancer and EGFR-mutant NSCLC, providing meaningful clinical benefit with a manageable safety profile. Optimal sequencing and positioning within the rapidly shifting ADC landscape requires further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251393259","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:35:51Z","timestamp":1764585351000},"page":"486-499","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8419-1230","authenticated-orcid":false,"given":"Rachel","family":"Lucky","sequence":"first","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-9447","authenticated-orcid":false,"given":"Lauren","family":"Thornburg","sequence":"additional","affiliation":[{"name":"Regional One Health, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6611"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_2_7_2","unstructured":"Datroway (Datopotamab deruxtecan) [prescribing information]. Daiichi Sankyo Inc. June; 2025."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_2_9_2","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer. Accessed August 1 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117863"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28385"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.009"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03266-2"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03267-1"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01349"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8501"},{"key":"e_1_3_2_22_2","unstructured":"National Cancer Comprehensive Network. Antiemesis (Version 2.2025). Published May 12 2025. Accessed August 1 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"e_1_3_2_23_2","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 4.2025). Published April 17 2025. Accessed November 3 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0188"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2354162"},{"key":"e_1_3_2_26_2","unstructured":"Trodelvy (sacituzumab govitecan) [prescribing information]. Gilead Sciences Inc. March; 2025."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02766-9"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.180"},{"key":"e_1_3_2_30_2","unstructured":"National Cancer Comprehensive Network. Non-small cell lung cancer (Version 7.2025). Published July 10 2025. Accessed August 1 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107248"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251393259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251393259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251393259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:26Z","timestamp":1777374866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251393259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/10600280251393259"],"URL":"https:\/\/doi.org\/10.1177\/10600280251393259","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}